Merrimack Pharmaceuticals Inc (MACK) 7.29 $MACK
Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress
GlobeNewswire - Fri Sep 19, 6:59AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present clinical data on three novel antibody cancer therapeutics at the ESMO (European Society for Medical Oncology) 2014 Congress, September 26-30 in Madrid. Presentations will include a combined biomarker analysis of MM-121 across three Phase 2 studies, MM-111 Phase 1 biomarker data and updated Phase 1 safety and clinical activity for MM-151.
5 Stocks Under $10 Soaring Higher
at The Street - Fri Sep 12, 7:59AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Market Has Not Yet Noticed Potential in Merrimack Pharmaceuticals (MACK); Have You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 7:39AM CDT
Merrimack Pharmaceuticals is one such company that looks well positioned for a solid gain, but has been overlooked by investors
Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 7:43AM CDT
Merrimack Pharmaceuticals has been witnessing a narrow down in its loss estimates for past 1 month, while its share price increased 5.4%
Will Merrimack Pharmaceuticals (MACK) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 7:54AM CDT
Merrimack Pharmaceuticals, a firm in the healthcare sector, which could be a great candidate for another earnings beat
Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval
GlobeNewswire - Mon Aug 11, 6:07AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the initiation of a global, open-label, randomized Phase 2 trial of MM-302, a HER2-targeted nanoliposomal encapsulation of doxorubicin, in combination with trastuzumab (Herceptin(R)) in patients with HER2-positive locally advanced or metastatic breast cancer. The trial was designed with input from the U.S. Food and Drug Administration (FDA) to support a potential accelerated approval application.
Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results
GlobeNewswire - Mon Aug 11, 6:07AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, today announced its second quarter 2014 financial results. Merrimack will host a live conference call and webcast today, Monday, August 11 at 8:00 a.m., Eastern Time, to provide an update on Merrimack's progress as well as a summary of second quarter 2014 financial results.
Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax
PR Newswire - Thu Aug 07, 7:50AM CDT
On Wednesday, August 06, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average finished the day 0.08% higher at 16,443.34, and the S&P 500 closed flat at 1,920.24. However the gains were not broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, and the index has declined 2.91% in the last one month. Investor-Edge has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Sangamo BioSciences Inc. (NASDAQ: SGMO), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Dyax Corporation (NASDAQ: DYAX). Free research on these five companies can be accessed at:
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call
GlobeNewswire - Mon Aug 04, 3:01PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Second Quarter 2014 Investor Conference Call and webcast at 8:00 a.m., Eastern time, on Monday, August 11.
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics
PR Newswire - Fri Jun 27, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding Akorn, Inc. (NASDAQ: AKRX), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Avanir Pharmaceuticals (NASDAQ: AVNR), Omeros Corporation (NASDAQ: OMER) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4189-100free.
Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer
GlobeNewswire - Wed Jun 25, 3:05PM CDT
MM-398 in combination with 5-fluorouracil and leucovorin shows statistically significant improvement in overall survival, progression free survival and overall response rate in patients with post-gemcitabine metastatic pancreatic cancer
Insider Trading Alert - MACK, POOL And GPS Traded By Insiders
at The Street - Wed Jun 25, 12:30PM CDT
Stocks with insider trader activity include MACK, POOL and GPS
5 Stocks With Big Insider Buying
at The Street - Wed Jun 25, 11:53AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
GARY L. CROCKER of Merrimack Pharmaceuticals, Inc. (MACK)-Nasdaq bought Shares of MACK
M2 - Wed Jun 25, 9:16AM CDT
Reported by InsiderCow.com at 2014-06-24 09:15:48 ET
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity
PR Newswire - Wed Jun 25, 7:15AM CDT
Biotech sector sees progress as companies develop advanced cancer therapeutics resulting in significant clinical data; company reaches agreement to develop drug aiding cancer treatment: GenSpera, Inc. (OTC: GNSZ), Seattle Genetics Inc. (NASDAQ: SGEN), (Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), OXiGENE, Inc. (NASDAQ: OXGN) and MerriMack Pharmaceuticals, Inc. (NASDAQ: MACK)
Why Micron Technology, Qihoo 360, and Merrimack Pharmaceuticals Rose Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Jun 24, 7:03PM CDT
On Tuesday, the stock market fell substantially, giving up what could have been another record run that would have marked the 12th time the Dow had hit all-time highs in 2014. Early in the session, bullish investors focused on solid economic data...
Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 3:45PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) fell after the company announced that Sanofi (SNY) will give up its development and commercialization rights to oncology candidate, MM-121.
Merrimack Pharmaceuticals (MACK) Crumbles: Stock Tanks by 11.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:33AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) saw a big move last session, continuing the recent downtrend for MACK, as the stock is now down 13.6% since May 29, 2014
2 Top Catalysts This Week: AstraZeneca and Merrimack
George Budwell, The Motley Fool - Motley Fool - Sun Jun 22, 8:30AM CDT
Let's take a look at next week's top health care and biotech catalysts. Keep an eye out AstraZeneca and Merrimack Pharmaceuticals . AstraZeneca's ovarian cancer drug set to be reviewed next week AstraZeneca decided to repeatedly rebuff ...
Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress
GlobeNewswire - Fri Sep 19, 6:59AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present clinical data on three novel antibody cancer therapeutics at the ESMO (European Society for Medical Oncology) 2014 Congress, September 26-30 in Madrid. Presentations will include a combined biomarker analysis of MM-121 across three Phase 2 studies, MM-111 Phase 1 biomarker data and updated Phase 1 safety and clinical activity for MM-151.
5 Stocks Under $10 Soaring Higher
at The Street - Fri Sep 12, 7:59AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Market Has Not Yet Noticed Potential in Merrimack Pharmaceuticals (MACK); Have You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 7:39AM CDT
Merrimack Pharmaceuticals is one such company that looks well positioned for a solid gain, but has been overlooked by investors
Can Merrimack Pharmaceuticals (MACK) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 7:43AM CDT
Merrimack Pharmaceuticals has been witnessing a narrow down in its loss estimates for past 1 month, while its share price increased 5.4%
Will Merrimack Pharmaceuticals (MACK) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 7:54AM CDT
Merrimack Pharmaceuticals, a firm in the healthcare sector, which could be a great candidate for another earnings beat
Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval
GlobeNewswire - Mon Aug 11, 6:07AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the initiation of a global, open-label, randomized Phase 2 trial of MM-302, a HER2-targeted nanoliposomal encapsulation of doxorubicin, in combination with trastuzumab (Herceptin(R)) in patients with HER2-positive locally advanced or metastatic breast cancer. The trial was designed with input from the U.S. Food and Drug Administration (FDA) to support a potential accelerated approval application.
Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results
GlobeNewswire - Mon Aug 11, 6:07AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, today announced its second quarter 2014 financial results. Merrimack will host a live conference call and webcast today, Monday, August 11 at 8:00 a.m., Eastern Time, to provide an update on Merrimack's progress as well as a summary of second quarter 2014 financial results.
Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax
PR Newswire - Thu Aug 07, 7:50AM CDT
On Wednesday, August 06, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average finished the day 0.08% higher at 16,443.34, and the S&P 500 closed flat at 1,920.24. However the gains were not broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, and the index has declined 2.91% in the last one month. Investor-Edge has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Sangamo BioSciences Inc. (NASDAQ: SGMO), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Dyax Corporation (NASDAQ: DYAX). Free research on these five companies can be accessed at:
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call
GlobeNewswire - Mon Aug 04, 3:01PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Second Quarter 2014 Investor Conference Call and webcast at 8:00 a.m., Eastern time, on Monday, August 11.
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics
PR Newswire - Fri Jun 27, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding Akorn, Inc. (NASDAQ: AKRX), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Avanir Pharmaceuticals (NASDAQ: AVNR), Omeros Corporation (NASDAQ: OMER) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4189-100free.
Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer
GlobeNewswire - Wed Jun 25, 3:05PM CDT
MM-398 in combination with 5-fluorouracil and leucovorin shows statistically significant improvement in overall survival, progression free survival and overall response rate in patients with post-gemcitabine metastatic pancreatic cancer
Insider Trading Alert - MACK, POOL And GPS Traded By Insiders
at The Street - Wed Jun 25, 12:30PM CDT
Stocks with insider trader activity include MACK, POOL and GPS
5 Stocks With Big Insider Buying
at The Street - Wed Jun 25, 11:53AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
GARY L. CROCKER of Merrimack Pharmaceuticals, Inc. (MACK)-Nasdaq bought Shares of MACK
M2 - Wed Jun 25, 9:16AM CDT
Reported by InsiderCow.com at 2014-06-24 09:15:48 ET
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity
PR Newswire - Wed Jun 25, 7:15AM CDT
Biotech sector sees progress as companies develop advanced cancer therapeutics resulting in significant clinical data; company reaches agreement to develop drug aiding cancer treatment: GenSpera, Inc. (OTC: GNSZ), Seattle Genetics Inc. (NASDAQ: SGEN), (Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), OXiGENE, Inc. (NASDAQ: OXGN) and MerriMack Pharmaceuticals, Inc. (NASDAQ: MACK)
Why Micron Technology, Qihoo 360, and Merrimack Pharmaceuticals Rose Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Jun 24, 7:03PM CDT
On Tuesday, the stock market fell substantially, giving up what could have been another record run that would have marked the 12th time the Dow had hit all-time highs in 2014. Early in the session, bullish investors focused on solid economic data...
Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 3:45PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) fell after the company announced that Sanofi (SNY) will give up its development and commercialization rights to oncology candidate, MM-121.
Merrimack Pharmaceuticals (MACK) Crumbles: Stock Tanks by 11.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:33AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) saw a big move last session, continuing the recent downtrend for MACK, as the stock is now down 13.6% since May 29, 2014
2 Top Catalysts This Week: AstraZeneca and Merrimack
George Budwell, The Motley Fool - Motley Fool - Sun Jun 22, 8:30AM CDT
Let's take a look at next week's top health care and biotech catalysts. Keep an eye out AstraZeneca and Merrimack Pharmaceuticals . AstraZeneca's ovarian cancer drug set to be reviewed next week AstraZeneca decided to repeatedly rebuff ...
